Sign In
Buy DMAC
$6.34
-0.170 (-2.61%)
At Close: Jul 31, 2026
DiaMedica Therapeutics Inc. (DMAC) Q4 2022 Earnings Call Transcript
10:01am, Wednesday, 29'th Mar 2023
DiaMedica Therapeutics Inc. (NASDAQ:DMAC ) Q4 2022 Earnings Conference Call March 29, 2023 8:00 AM ET Company Participants Rick Pauls - President and Chief Executive Officer Scott Kellen - Chief Finan
DiaMedica Therapeutics to Report Fourth Quarter 2023 Financial Results and Provide a Business Update March 29, 2023
04:17pm, Monday, 20'th Mar 2023
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute
DiaMedica Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference
08:00am, Monday, 13'th Mar 2023
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseas
What Makes DiaMedica Therapeutics, Inc. (DMAC) a New Buy Stock
01:33pm, Wednesday, 02'nd Nov 2022
DiaMedica Therapeutics, Inc. (DMAC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
DiaMedica Therapeutics to Present at Credit Suisse 31st Annual Healthcare Conference
08:32am, Monday, 31'st Oct 2022
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseas
DiaMedica Therapeutics to Present at Lake Street's 6th Annual Best Ideas Growth Conference
04:10pm, Tuesday, 06'th Sep 2022
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseas
DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q2 2022 Results - Earnings Call Transcript
12:01pm, Thursday, 11'th Aug 2022
DiaMedica Therapeutics Inc. (NASDAQ:DMAC ) Q2 2022 Earnings Conference Call August 11, 2022 8:00 AM ET Company Participants Rick Pauls - President and Chief Executive Officer Kirsten Gruis - Chief Med
DiaMedica Therapeutics to Report Second Quarter 2022 Financial Results and Provide a Business Update August 11, 2022
08:12am, Thursday, 04'th Aug 2022
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseas
FDA Institutes Clinical Hold On DiaMedica's Late-Stage Stroke Trial - Read Why
07:51am, Thursday, 07'th Jul 2022
The FDA placed a clinical hold on DiaMedica Therapeutics Inc's (NASDAQ: DMAC) Phase 2/3 ReMEDy2 trial evaluating DM199 to treat acute ischemic stroke patients. The clinical hold was initiated f
DiaMedica Therapeutics to Attend the 19th Annual Craig-Hallum Institutional Investor Conference Wednesday, June 1, 2022
04:15pm, Wednesday, 25'th May 2022
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseas
DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q1 2022 Results - Earnings Call Transcript
09:09pm, Friday, 06'th May 2022
DiaMedica Therapeutics Inc. (NASDAQ:DMAC ) Q1 2022 Earnings Conference Call May 5, 2022 8:00 AM ET Company Participants Rick Pauls - President and Chief Executive Officer Kirsten Gruis - Chief Medical
DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q4 2021 Results - Earnings Call Transcript
12:20pm, Tuesday, 15'th Mar 2022
DiaMedica Therapeutics Inc. (DMAC) CEO Rick Pauls on Q4 2021 Results - Earnings Call Transcript
DiaMedica Therapeutics to Report Fourth Quarter 2021 Financial Results and Provide a Business Update March 15, 2022
08:13am, Tuesday, 08'th Mar 2022
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseas
DiaMedica Therapeutics to Present Research at International Stroke Conference
08:43am, Tuesday, 25'th Jan 2022
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseas
Zacks: Analysts Expect DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Will Announce Earnings of -$0.16 Per Share
05:10pm, Wednesday, 22'nd Dec 2021 Transcript Daily
Wall Street analysts expect DiaMedica Therapeutics Inc. (NASDAQ:DMAC) to post earnings of ($0.16) per share for the current quarter, according to Zacks. Zero analysts have made estimates for DiaMedica Therapeutics earnings, with estimates ranging from ($0.17) to ($0.15). DiaMedica Therapeutics posted earnings per share of ($0.23) in the same quarter last year, which suggests a []
